← All trials
NCT04429295
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2020
- Primary completion
- Nov 29, 2020
- Completion date
- Mar 4, 2022
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 460
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- inactivated poliovirus type 2 vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- bivalent oral polio vaccine (bopv), type 1 and type 3
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.